Business
Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026 Initiation of Second Phase 3 Study, LEVEL-2, Expected This Year CHAPEL HILL, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today reported financial results for th
About this update from Tenax Therapeutics, Inc.
[{"type":"image","alt":"Tenax Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Tenax Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":86,"url":"https://media.zenfs.com/en/globenewswire.com/086764dfb6bc07a5373ff5909c69dd8a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0Yzp0.DOU_ACRbjGKAg31w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/086764dfb6bc07a5373ff5909c69dd8a","width":300,"height":86}},"lazy":false},{"type":"text","content":"Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026","length":132,"tagName":"p"},{"type":"text","content":"Initiation of Second Phase 3 Study, LEVEL-2, Expected This Year","length":63,"tagName":"p"},{"type":"text","content":"CHAPEL HILL, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today reported financial results for the quarter ended March 31, 2025 and provided an update on its recent corporate progress.","length":390,"tagName":"p"},{"type":"text","content":"“2025 is off to a strong start. We continued to make meaningful progress in both the ongoing LEVEL study as well as preparations to commence our second registrational Phase 3 study, LEVEL-2,” said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics. “We also continued to engage with key stakeholders over the past quarter to discuss how levosimendan can control splanchnic blood volume and reduce blood flow to the left ventricle, potentially providing desirable effects for patients suffering from PH-HFpEF. We expect to share topline data from our first Phase 3 study, LEVEL, in the middle of 2026 and establish TNX-103 as a powerful therapeutic option for this disease currently without any available treatments.”","length":741,"tagName":"p"},{"type":"text","content":"Recent Corporate and Clinical Highlights","length":40,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Patient enrollment in the Phase 3 LEVEL study of TNX-103 in PH-HFpEF continues, with high rates of study and therapy continuation during the blinded and ope...